First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma

Nom du journal : Cancer Immunol Immunother

Année : 2021

Volume : 71

Page de départ : 417

Page de fin : 431

Auteurs: Gao B, Vosganian G, Parikh A, Lambert S, Englert S, Afar DE, Warburton L, Millward M, Lin CC, Peltola KJ, Alanko T, Cervantes A, Moreno V, Calvo E, Tosi D, Cassier PA, Gazzah A, Italiano A, Shiah HS, Roda D, Tanner M,